20,160 recalled units and therapy lost at high pressure

BMC Medical Co., Ltd. reported a recall on July 15, 2026, the Food and Drug Administration restated wellness policy on January 6, 2026, and the agency classified the Luna action as Class I on August 19, 2026. Those events covered 20,160 Luna G3 APAP Model LG3600 units in the United States.

The policy document is called General Wellness: Policy for Low Risk Devices. It supersedes the 2019 guidance and covers low risk products said to support a healthy lifestyle.

Software functions meant only to maintain or encourage a healthy lifestyle without connection to diagnosis, cure, mitigation, prevention or treatment fall outside the medical device definition under Section 520(o)(1)(B). Non-software products with the same purpose receive enforcement discretion, which means the agency does not plan to enforce requirements under the Federal Food, Drug, and Cosmetic Act.

The policy leaves out drugs, biologics, dietary supplements, foods, cosmetics overseen by other FDA Centers and combination products. Non-invasive products that estimate blood pressure for wellness purposes can qualify when the intended use is strictly wellness focused and other conditions are satisfied.

A wearable that estimates blood glucose to track nutritional effects can qualify when it is specifically contraindicated for use with diabetics and pre-diabetics. A blood glucose wearable that uses minimally invasive microneedle technology is not low risk even when claims remain purely wellness oriented.

Sensor based wellness products lose the general wellness position when they prompt specific clinical action, provide treatment guidance, or measure for screening, diagnosis, monitoring or management of disease. They also lose that position when they claim to substitute for an FDA cleared device or when they include references to specific diseases or diagnostic thresholds.

The Luna G3 APAP recall showed where that boundary still holds. BMC Medical Co., Ltd. reported the action after identifying a firmware defect, and FDA assigned Recall Number Z-2979-2026.

Firmware version G3-2.00.76 could produce an error message followed by automatic shutdown and failure to deliver therapy under high pressure, high respiratory rate and high peak flow. BMC pushed firmware G3 2.00.77 to 20,160 units at the United States importers warehouse between October and December 2024, yet later flagged that up to 196 units may have missed the update. BMC reported zero complaints or serious adverse events as of the September 8, 2026 notice. Whether any units without the upgrade remain in active use is still unclear.

Forecasts suggest steady growth will continue on the wellness side of that line. The North America medical wellness devices market is pegged at US$44.4 billion in 2026 and seen rising to US$71.8 billion by 2033 at a compound annual growth rate of 7.1 percent. The model assigns the United States 80 percent market share in 2026, while Canada is listed as the fastest growing region.

Diabetic monitoring devices are expected to supply 37 percent of revenue in 2026, with retail sales seen above 62 percent. Consumer grade devices still draw scrutiny over uneven readings versus hospital grade gear, plus lingering data privacy worries.

Watch whether real 2026 retail sales meet the forecast, and how validation standards settle for daily trackers.